Clinical trials in Innsbruck – page 15

362 clinical trials in Innsbruck, Austria across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Innsbruck at a glance

362

clinical trials

Research sites2

Quick filters

362 trials in Innsbruck

Open in trial search

Anaemia+1

Not yet recruiting

Study of Elritercept (TAK‑226) with Ruxolitinib vs Placebo in Patients with Myelofibrosis and Anemia on Ruxolitinib Therapy

Registered drug

Study of Elritercept (TAK‑226) with Ruxolitinib vs Placebo in Patients with Myelofibrosis and Anemia on Ruxolitinib Therapy

Registered drug

Austria

Participants:18–64 years · 65+ years
Substances:Elritercept
Sponsor:Takeda Development Center Americas Inc.

Contact Research Centre

Pulmonary hypertension

Not yet recruiting

Long‑Term Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease

Investigational

Long‑Term Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease

Investigational

Austria

Participants:18–64 years · 65+ years
Substances:Treprostinil Palmitil
Sponsor:Insmed Inc.

Contact Research Centre

Efficacy of efgartigimod alfa as first‑line add‑on to IV methylprednisolone for moderate‑to‑severe attacks in patients with demyelinating diseases

Not yet recruiting

Registered drug

Efficacy of efgartigimod alfa as first‑line add‑on to IV methylprednisolone for moderate‑to‑severe attacks in patients with demyelinating diseases

Registered drug

Austria

Participants:18–64 years · 65+ years
Substances:Efgartigimod Alfa
Sponsor:Medizinische Hochschule Hannover

Contact Research Centre

Hereditary haemochromatosis

Not yet recruiting

A study to evaluate the effectiveness and safety of vamifeport in adults with hereditary hemochromatosis

Investigational

A study to evaluate the effectiveness and safety of vamifeport in adults with hereditary hemochromatosis

Investigational

Austria

Participants:18–64 years · 65+ years
Substances:Vamifeport trihydrochloride
Sponsor:CSL Behring LLC

Contact Research Centre

Chronic rhinosinusitis with nasal polyps

Not yet recruiting

Comparison of dupilumab and tezepelumab for the treatment of chronic rhinosinusitis with nasal polyps.

Registered drugNo placebo

Comparison of dupilumab and tezepelumab for the treatment of chronic rhinosinusitis with nasal polyps.

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Dupilumab
Sponsor:Medical University Of Vienna

Contact Research Centre

A study to evaluate the effect of xanomeline tartrate and trospium chloride on cognitive impairment in adults with schizophrenia.

Not yet recruiting

InvestigationalNo placebo

A study to evaluate the effect of xanomeline tartrate and trospium chloride on cognitive impairment in adults with schizophrenia.

InvestigationalNo placebo

Austria

Participants:18–64 years
Substances:Trospium Chloride
Sponsor:European Group for Research in Schizophrenia Stichting

Contact Research Centre

Plasma cell myeloma refractory

Not yet recruiting

A Study of Linvoseltamab Alone and Linvoseltamab with Carfilzomib Compared to Standard Treatment in Adults with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo

A Study of Linvoseltamab Alone and Linvoseltamab with Carfilzomib Compared to Standard Treatment in Adults with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Aciclovir
Sponsor:Regeneron Pharmaceuticals Inc.

Contact Research Centre

Testing inotuzumab ozogamicin and blinatumomab with drug combination for children with relapsed precursor B-cell acute lymphoblastic leukemia

Not yet recruiting

Registered drugNo placebo

Testing inotuzumab ozogamicin and blinatumomab with drug combination for children with relapsed precursor B-cell acute lymphoblastic leukemia

Registered drugNo placebo

Austria

Participants:0–17 years · 18–64 years
Substances:Blinatumomab
Sponsor:Charite Universitaetsmedizin Berlin KöR

Contact Research Centre

Fallopian tube cancer+1

Not yet recruiting

Study of TORL-1-23 and pegfilgrastim in women with advanced platinum-resistant ovarian, peritoneal, or fallopian tube cancer expressing CLDN6

Registered drugNo placebo

Study of TORL-1-23 and pegfilgrastim in women with advanced platinum-resistant ovarian, peritoneal, or fallopian tube cancer expressing CLDN6

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Glatiramer Acetate
Sponsor:Torl Biotherapeutics LLC

Contact Research Centre

Systemic lupus erythematosus+1

Not yet recruiting

Study on the Effects of Rapcabtagene Autoleucel in Patients with Systemic Lupus Erythematosus and Active, Refractory Lupus Nephritis

Registered drugNo placebo

Study on the Effects of Rapcabtagene Autoleucel in Patients with Systemic Lupus Erythematosus and Active, Refractory Lupus Nephritis

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Azathioprine
Sponsor:Novartis Pharma AG

Contact Research Centre

Narcolepsy

Not yet recruiting

Study on TAK-861 for Treating Narcolepsy with Cataplexy in Patients

Investigational

Study on TAK-861 for Treating Narcolepsy with Cataplexy in Patients

Investigational

Austria

Participants:18–64 years · 65+ years
Substances:N-{(2S,3R)-4,4-Difluoro-1-(2-Hydroxy-2-Methylpropanoyl)-2-[(2,3',5'-Trifluoro[1,1'-Biphenyl]-3-Yl)Methyl]Pyrrolidin-3-Yl}Ethanesulfonamide
Sponsor:Takeda Development Center Americas Inc.

Contact Research Centre

Neoplasm malignant

Not yet recruiting

Study on the Effectiveness and Safety of Luveltamab Tazevibulin Compared to Chemotherapy in Women with Relapsed Platinum-resistant Ovarian Cancer

Registered drugNo placebo

Study on the Effectiveness and Safety of Luveltamab Tazevibulin Compared to Chemotherapy in Women with Relapsed Platinum-resistant Ovarian Cancer

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Gemcitabine
Sponsor:Sutro Biopharma Inc.

Contact Research Centre

Other cities in Austria

The busiest research cities in the country

All 47 cities in Austria

Clinical research in Innsbruck

What the registry says about research in the country

01 Oncology Research

Advanced clinical trials focusing on innovative treatments for various cancers, including bladder cancer, breast cancer, and gastric cancer. Studies evaluate novel combination therapies and targeted treatments to improve patient outcomes.

Non-muscle invasive bladder cancer treatment
HER2-positive cancer therapies
Glioblastoma management

Research emphasizes personalized medicine approaches and innovative drug combinations.

02 Neurological Disorders

Groundbreaking studies examining treatments for multiple sclerosis and other neurological conditions. Research focuses on testing new therapeutic agents and evaluating their effectiveness in managing disease progression.

Multiple sclerosis treatment innovations
Brain structure and function studies
Neurological response assessment

Trials aim to advance understanding of disease mechanisms and improve treatment outcomes.

03 Inflammatory Conditions

Clinical investigations into chronic inflammatory diseases, including Crohn's Disease and ulcerative colitis. Studies evaluate novel therapeutic approaches and combination treatments.

Gastrointestinal inflammation management
Chronic rhinosinusitis treatment
Inflammatory response modulation

Research focuses on improving quality of life for patients with chronic inflammatory conditions.

Back to Austria All countries